TY - JOUR
T1 - Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation
AU - Ohto, Umeharu
AU - Kamitsukasa, Yukie
AU - Ishida, Hanako
AU - Zhang, Zhikuan
AU - Murakami, Karin
AU - Hirama, Chie
AU - Maekawa, Sakiko
AU - Shimizu, Toshiyuki
N1 - Funding Information:
ACKNOWLEDGMENTS. We thank Masahide Kikkawa, Haruaki Yanagisawa, Yoichi Sakamaki, and Yoshiaki Kise for the management and support of the Graduate School of Medicine cryo-EM facility at The University of Tokyo. This work was supported by a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science, and Technology Grant Nos. 19H03164 (U.O.), 20K16274 (H.I.), 20K15730 (Z.Z.), 19H00976 (T.S.); Core Research for Evolutional Science & Technology (CREST), Japan Science & Technology Agency (JST) (T.S.); Sumitomo Dainippon Pharma Co., Ltd. (T.S.); the Takeda Science Foundation (U.O. and T.S.); the Mochida Memorial Foundation for Medical and Pharmaceutical Research (U.O.); the Daiichi Sankyo Foundation of Life Science (U.O.); the Uehara Memorial Foundation (T.S.); and the Naito Foundation (U.O. and T.S.); the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) from Japan Agency for Medical Research and Development (AMED) under Grant No. JP21am0101115 (support No. 1570, 1846, 1848).
Publisher Copyright:
© 2022 National Academy of Sciences. All rights reserved.
PY - 2022/3/15
Y1 - 2022/3/15
N2 - The nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) responds to a vast variety of stimuli, and activated NLRP3 forms an inflammasome, which in turn is associated with conditions such as atherosclerosis, Alzheimer's disease, and diabetes. A multilayered regulatory mechanism ensures proper NLRP3 inflammasome activation, although the structural basis for this process remains unclear. This study aimed to investigate the cryo-electron microscopy structure of the dodecameric form of full-length NLRP3 bound to the clinically relevant NLRP3-specific inhibitor MCC950. The inhibitor binds to the cavity distinct from the nucleotide binding site in the NACHT domain and stabilizes the closed conformation of NLRP3. The barrel-shaped dodecamer composed of the inactive form of NLRP3 is formed mainly through LRR-LRR interactions on the lateral side, and the highly positively charged top and bottom sides composed of NACHT domains provide a scaffold for membrane association. The cryo-electron microscopy structure suggests that oligomerization of NLRP3 is necessary for its membrane association; it is subsequently disrupted for activation, hence serving as a key player in controlling the spatiotemporal NLRP3 inflammasome activation. These findings are expected to contribute to the development of drugs targeting NLRP3 in future.
AB - The nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) responds to a vast variety of stimuli, and activated NLRP3 forms an inflammasome, which in turn is associated with conditions such as atherosclerosis, Alzheimer's disease, and diabetes. A multilayered regulatory mechanism ensures proper NLRP3 inflammasome activation, although the structural basis for this process remains unclear. This study aimed to investigate the cryo-electron microscopy structure of the dodecameric form of full-length NLRP3 bound to the clinically relevant NLRP3-specific inhibitor MCC950. The inhibitor binds to the cavity distinct from the nucleotide binding site in the NACHT domain and stabilizes the closed conformation of NLRP3. The barrel-shaped dodecamer composed of the inactive form of NLRP3 is formed mainly through LRR-LRR interactions on the lateral side, and the highly positively charged top and bottom sides composed of NACHT domains provide a scaffold for membrane association. The cryo-electron microscopy structure suggests that oligomerization of NLRP3 is necessary for its membrane association; it is subsequently disrupted for activation, hence serving as a key player in controlling the spatiotemporal NLRP3 inflammasome activation. These findings are expected to contribute to the development of drugs targeting NLRP3 in future.
KW - NLRP3
KW - NOD-like receptor
KW - inflammasome
UR - http://www.scopus.com/inward/record.url?scp=85125969042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125969042&partnerID=8YFLogxK
U2 - 10.1073/pnas.2121353119
DO - 10.1073/pnas.2121353119
M3 - Article
C2 - 35254907
AN - SCOPUS:85125969042
SN - 0027-8424
VL - 119
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 11
M1 - e2121353119
ER -